Live event: Thursday 10 August 2017, 11:00 AM [CT]
Not your time zone? Please find the conversion here.
A Senior Scientific Advisor at EAG Laboratories, Dr. Glenn Petrie has more than 20 years of experience in the drug development arena with a focus on biopharmaceuticals. As a director at a major CRO he served as team leader in the development, Chemistry Manufacture and Control (CMC) design and IND submissions for a wide variety of biopharmaceuticals (monoclonal antibodies, drug conjugates, peptides, etc.). A subject matter expert in the analysis of proteins including HPLC, mass spectroscopy, ELISAs and electrophoresis, Dr. Petrie received his B.A. in Biochemistry from Rice University and his doctorate in Biochemistry from the University of Illinois Urbana-Champaign.
In this webinar, Glenn Petrie discusses the key to rapid investigational new drug submission and approval in Antibody Drug Conjugates (ADCs) developlment. ADCs are a growing segment of the biopharmaceutical pipeline with currently dozens of ADCs in clinical trials and an estimated 150 in pre-clinical development. ADCs consist of a payload (toxin) covalently linked to a targeting sub-unit (monoclonal antibody). The vast majority of ADCs are utilized for the treatment of solid and hematological cancers. The antibody sub-unit binds to the cancer cell surface and the ADC is internalized to the cell cytoplasm. The endosome fuses with lysosomes resulting in cleavage of the linker, release of the free cytotoxin and cell death.Register Now For more webinars from our expert series click here